Polycomb group proteins are key regulators of keratinocyte function
- PMID: 21085188
- PMCID: PMC3045731
- DOI: 10.1038/jid.2010.318
Polycomb group proteins are key regulators of keratinocyte function
Abstract
The Polycomb group (PcG) proteins are epigenetic suppressors of gene expression that function through modification of histones to change chromatin structure and modulate gene expression and cell behavior. Recent studies show that PcG proteins are expressed in epidermis, that their levels change during differentiation and in disease states, and that PcG expression is regulated by agents that influence cell proliferation and survival. The results indicate that PcG proteins regulate keratinocyte cell-cycle progression, apoptosis, senescence, and differentiation. These proteins are expressed in progenitor cells, in the basal layer, and in suprabasal keratinocytes, and the level, timing, and distribution of expression suggest that the PcG proteins have a central role in maintaining the balance between cell survival and death in multiple epidermal compartments. Additional studies indicate an important role in skin cancer progression.
Conflict of interest statement
The authors state no conflict of interest.
Figures


Similar articles
-
The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.Carcinogenesis. 2010 Mar;31(3):496-503. doi: 10.1093/carcin/bgp314. Epub 2009 Dec 16. Carcinogenesis. 2010. PMID: 20015867 Free PMC article.
-
The role of polycomb group proteins in cell cycle regulation during development.Cell Cycle. 2006 Jun;5(11):1189-97. doi: 10.4161/cc.5.11.2781. Epub 2006 Jun 1. Cell Cycle. 2006. PMID: 16721063 Review.
-
Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis.Exp Hematol. 2003 Jul;31(7):567-85. doi: 10.1016/s0301-472x(03)00081-x. Exp Hematol. 2003. PMID: 12842702 Review.
-
Pathways involved in proliferating, senescent and immortalized keratinocyte cell death mediated by two different TRAIL preparations.Exp Dermatol. 2002 Dec;11(6):573-83. doi: 10.1034/j.1600-0625.2002.110610.x. Exp Dermatol. 2002. PMID: 12473065
-
Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective.Stem Cells. 2007 Oct;25(10):2498-510. doi: 10.1634/stemcells.2006-0608. Epub 2007 Jun 28. Stem Cells. 2007. PMID: 17600113 Review.
Cited by
-
The molecular genetics of eyelid tumors: recent advances and future directions.Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):419-33. doi: 10.1007/s00417-012-2248-5. Epub 2012 Dec 30. Graefes Arch Clin Exp Ophthalmol. 2013. PMID: 23275038 Review.
-
Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma.Int J Clin Exp Pathol. 2017 Aug 1;10(8):8928-8935. eCollection 2017. Int J Clin Exp Pathol. 2017. PMID: 31966762 Free PMC article.
-
MEP50/PRMT5 Reduces Gene Expression by Histone Arginine Methylation and this Is Reversed by PKCδ/p38δ Signaling.J Invest Dermatol. 2016 Jan;136(1):214-224. doi: 10.1038/JID.2015.400. J Invest Dermatol. 2016. PMID: 26763441 Free PMC article.
-
The Bmi-1 helix-turn and ring finger domains are required for Bmi-1 antagonism of (-) epigallocatechin-3-gallate suppression of skin cancer cell survival.Cell Signal. 2015 Jul;27(7):1336-44. doi: 10.1016/j.cellsig.2015.03.021. Epub 2015 Apr 2. Cell Signal. 2015. PMID: 25843776 Free PMC article.
-
Sulforaphane suppresses polycomb group protein level via a proteasome-dependent mechanism in skin cancer cells.Mol Pharmacol. 2011 Nov;80(5):870-8. doi: 10.1124/mol.111.072363. Epub 2011 Aug 1. Mol Pharmacol. 2011. PMID: 21807989 Free PMC article.
References
-
- Ahmad N, Mukhtar H. Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev. 1999;57:78–83. - PubMed
-
- Aoto T, Saitoh N, Sakamoto Y, et al. Polycomb group protein-associated chromatin is reproduced in post-mitotic G1 phase and is required for S phase progression. J Biol Chem. 2008;283:18905–18915. - PubMed
-
- Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006;24:268–273. - PubMed
-
- Bachmann IM, Puntervoll HE, Otte AP, et al. Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol. 2008;21:583–590. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources